Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Leases (2019 - 2026)

Corvus Pharmaceuticals' Current Leases history spans 8 years, with the latest figure at $428000.0 for Q1 2026.

  • Quarterly Current Leases rose 34.17% to $428000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $428000.0 through Mar 2026, up 34.17% year-over-year, with the annual reading at $403000.0 for FY2025, 117.84% up from the prior year.
  • Current Leases came in at $428000.0 for Q1 2026, up from $403000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.4 million in Q4 2023 to a low of $185000.0 in Q4 2024.
  • The 5-year median for Current Leases is $1.0 million (2024), against an average of $827588.2.
  • Year-over-year, Current Leases tumbled 86.54% in 2024 and then skyrocketed 117.84% in 2025.
  • Corvus Pharmaceuticals' Current Leases stood at $1.2 million in 2022, then rose by 11.89% to $1.4 million in 2023, then crashed by 86.54% to $185000.0 in 2024, then surged by 117.84% to $403000.0 in 2025, then increased by 6.2% to $428000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Current Leases are $428000.0 (Q1 2026), $403000.0 (Q4 2025), and $379000.0 (Q3 2025).